PubRank

Keith B Glaser

Author PubWeight™ 31.52‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci 2010 2.47
2 Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009 2.14
3 Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006 1.32
4 ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 2007 1.26
5 G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest 2007 1.16
6 Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem 2007 1.11
7 Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate and a secondary trypsin reaction. Anal Biochem 2004 1.07
8 Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J Med Chem 2005 1.04
9 1-Benzyl-3-cetyl-2-methylimidazolium iodide (NH125) induces phosphorylation of eukaryotic elongation factor-2 (eEF2): a cautionary note on the anticancer mechanism of an eEF2 kinase inhibitor. J Biol Chem 2011 1.00
10 Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett 2002 0.99
11 Expression and functional characterization of recombinant human HDAC1 and HDAC3. Life Sci 2004 0.93
12 Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2008 0.93
13 Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 2006 0.91
14 ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. J Hepatol 2008 0.91
15 Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization. Proc Natl Acad Sci U S A 2010 0.87
16 ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol Cancer Ther 2010 0.86
17 3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases. J Med Chem 2008 0.84
18 Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo. Int J Oncol 2007 0.83
19 In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. Leuk Res 2007 0.83
20 Cyanobacterial Microcystis aeruginosa lipopolysaccharide elicits release of superoxide anion, thromboxane B₂, cytokines, chemokines, and matrix metalloproteinase-9 by rat microglia. Toxicol Sci 2011 0.82
21 Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC). Bioorg Med Chem Lett 2002 0.82
22 Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett 2003 0.82
23 Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases. Bioorg Med Chem Lett 2011 0.82
24 Isoindolinone ureas: a novel class of KDR kinase inhibitors. Bioorg Med Chem Lett 2004 0.82
25 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. J Med Chem 2008 0.81
26 A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett 2003 0.81
27 Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Bioorg Med Chem Lett 2007 0.80
28 Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families. Bioorg Med Chem Lett 2012 0.80
29 Thienopyridine urea inhibitors of KDR kinase. Bioorg Med Chem Lett 2006 0.79
30 The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway. Mol Cancer Ther 2011 0.78
31 Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett 2003 0.78
32 Defining the role of gene regulation in resistance to HDAC inhibitors--mechanisms beyond P-glycoprotein. Leuk Res 2005 0.76
33 Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett 2006 0.75
34 Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors. Bioorg Med Chem Lett 2012 0.75
35 Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases. Bioorg Med Chem Lett 2012 0.75
36 Indole amide hydroxamic acids as potent inhibitors of histone deacetylases. Bioorg Med Chem Lett 2003 0.75